Stay updated on SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.

Latest updates to the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page
- Check4 days agoChange DetectedThe record for the SNS-101 study is displayed with its trial design, eligibility criteria, locations, and outcome measures. It indicates the study is completed and no longer recruiting, and that the planned Phase 2 Part C was not initiated.SummaryDifference74%

- Check11 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA banner announces NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence.” The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check39 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1. The page continues to show a 403 error instead of the study record.SummaryDifference0.2%

- Check53 days agoChange DetectedThe study page now shows a 403 Forbidden error, indicating the record is temporarily inaccessible. This reflects an access issue rather than a content update to the study details.SummaryDifference21%

- Check60 days agoChange DetectedRevision v3.7.0 was applied, replacing the previous v3.6.6. This indicates an update to the page framework or template rather than new or removed study information.SummaryDifference0.0%

Stay in the know with updates to SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.